Lazzari, Luca
IFOM
8 papers on CoChatORCID 0000-0001-6841-4240
Most cited papers
- Verified
Gut vascular barrier impairment leads to intestinal bacteria dissemination and colorectal cancer metastasis to liver
Bertocchi, A., Carloni, S., Ravenda, P. S., Bertalot, G., Spadoni, I., Lo Cascio, A., Gandini, S., Lizier, M., Braga, D., Asnicar, F., et al. (2021) · Cancer Cell
Cancer Cells and MetastasisGut microbiota and health
Cited by 515
- Verified
ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer
Pietrantonio, F., Di Nicolantonio, F., Schrock, A. B., Lee, J., Tejpar, S., Sartore-Bianchi, A., Hechtman, J. F., Christiansen, J., Novara, L., Tebbutt, N., et al. (2017) · JNCI: Journal of the National Cancer Institute
Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations
Cited by 317
- Verified
Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer
Arena, S., Bellosillo, B., Siravegna, G., Martínez, A., Cañadas, I., Lazzari, L., Ferruz, N., Russo, M., Misale, S., González, I., et al. (2015) · Clinical Cancer Research
Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations
Cited by 271
- Verified
Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer
Misale, S., Arena, S., Lamba, S., Siravegna, G., Lallo, A., Hobor, S., Russo, M., Buscarino, M., Lazzari, L., Sartore-Bianchi, A., et al. (2014) · Science Translational Medicine
Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations
Cited by 263
- Verified
Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer
Van Emburgh, B. O., Arena, S., Siravegna, G., Lazzari, L., Crisafulli, G., Corti, G., Mussolin, B., Baldi, F., Buscarino, M., Bartolini, A., et al. (2016) · Nature Communications
Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations
Cited by 214
- Verified
A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin
Arena, S., Corti, G., Durinikova, E., Montone, M., Reilly, N. M., Russo, M., Lorenzato, A., Arcella, P., Lazzari, L., Rospo, G., et al. (2020) · Clinical Cancer Research
PARP inhibition in cancer therapyColorectal Cancer Treatments and Studies
Cited by 115
- Verified
MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations
Arena, S., Siravegna, G., Mussolin, B., Kearns, J. D., Wolf, B. B., Misale, S., Lazzari, L., Bertotti, A., Trusolino, L., Adjei, A. A., et al. (2016) · Science Translational Medicine
Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations
Cited by 93
- Verified
Pembrolizumab in MMR-proficient metastatic colorectal cancer pharmacologically primed to trigger dynamic hypermutation status: The ARETHUSA trial
Siena, S., Sartore-Bianchi, A., Personeni, N., Pietrantonio, F., Germano, G., Amatu, A., Bonoldi, E., Valtorta, E., Barault, L., Di Nicolantonio, F., et al. (2019) · Journal of Clinical Oncology
Cancer Immunotherapy and BiomarkersColorectal Cancer Treatments and Studies
Cited by 15
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free